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Introduction
Gliomas are the most common primary brain tumor in adults, representing about 81% of
malignant brain tumors (Ostrom et al., 2014). Gliomas are malignant and invasive tumors that
arise from glial tissue. Although it is a relatively rare disease, it can be devastating. Severe forms
of glioma spread throughout the brain, destroy normal brain tissue, and are resistant to treatment.
Gliomas can be classified in different ways. Gliomas can be categorized based on the
predominant cell type in the tumors as astrocytomas, oligodendrogliomas, or oligoastrocytomas
if the tumor has characteristics of both astrocytes and oligodendrocytes. The World Health
Organization (WHO) has also developed a grading system to classify gliomas on the basis of
malignancy (Louis et al., 2007). Grade I gliomas are benign and can be cured by surgical
resection. Grade II gliomas have a low malignancy but are often incurable with surgery. Grade
III gliomas are more proliferative and anaplastic than grade I. Grade IV gliomas are highly
malignant and characterized by rapid cell proliferation, high vascularization, and necrosis. Grade
IV gliomas are also known as glioblastomas.
The treatments currently available for malignant glioma are not very effective. The
current standard treatment involves surgical resection if possible, radiotherapy, chemotherapy,
and management of symptoms. Radiotherapy used with or without temozolomide (an oral
alkylating agent) is the mainstay of glioma treatment (Wen and Kesari, 2008). Radiotherapy may
increase survival from 3-4 months to 7-12 months, but after discontinuation of radiotherapy,
about 90% of tumors reoccur (Stupp et al., 2005; Hochberg and Pruitt, 1980).
There have been numerous studies on the cause of gliomas. So far it has been shown that
multiple molecular or genetic abnormalities can lead to the development of tumors. The Cancer
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Genome Atlas (TCGA) Research Network analyzed 206 glioblastoma samples and found three
core pathways that were altered in gliomas: 1) retinoblastoma (RB) pathway, 2) p53 pathway,
and 3) receptor tyrosine kinase (RTK) signaling (Cancer Genome Atlas Research Network,
2008). The mutations found within the RTK signaling pathways led to increased cell
proliferation and survival. One of the RTK pathways that they found to be altered was platelet
derived growth factor (PDGF) signaling through PDGF receptors (PDGFR). PDGFR alpha
(PDGFRa) alteration was also found to be a major feature of a molecular subtype of glioma
classified as the proneural subtype (Verhaak et al., 2010).
PDGF and PDGFRs have an important role in normal physiology. There are four known
members of the PDGF family: PDGF-A, B, C, and D (Hammacher et al., 1988). All PDGFs
have a highly conserved domain, called the PDGF/VEGF homology domain, which is involved
in forming the disulfide bridges to allow dimerization (Nazarenko et al., 2012). PDGF can form
30 kDa homodimers (PDGF-AA, BB, CC, DD) or heterodimers (PDGF-AB) that bind to
PDGFRa or PDGFR beta (PDGFRb), or both. PDGF-AA, AB, BB, and CC can all bind to
PDGFRa with high affinity, and PDGF-BB and DD bind to PDGFRb (Nister et al., 1991).
PDGFRs are membrane tyrosine kinase receptors (Heldin, 2013). PDGFRa is 1089 amino
acids and PDGFRb is 1106 amino acids, but they are structurally similar (Claesson-Welsh,
1996). Both have a single transmembrane domain in the middle of the polypeptide. They have an
extracellular domain consisting of five immunoglobulin-like domains (Claesson-Welsh, 1996).
The intracellular portion of the receptors consists of the juxtamembrane domain, the tyrosine
kinase domain, and the C-terminal domain (Claesson-Welsh, 1996). Ligands bind primarily to
the extracellular Ig-like domains 2 and 3 (Heldin, 2013). Binding of the ligands to PDGFR
induces dimerization of the receptor which allows transphosphorylation of the intracellular

Sakya 4

tyrosine kinase domain. Autophosphorylation changes the conformation of the intracellular
portion of the receptor which activates the kinase. The kinase activity of the receptor can initiate
downstream intracellular signaling pathways.
Signal transduction molecules that get phosphorylated by activated PDGFR all have a
homologous 100 amino acid stretch call the Src homology 2 (SH2) domain. This domain
recognizes the phosphorylated tyrosine residues of the receptor. About 10 families of SH2
domain containing molecules have been found to bind to PDGFR and become activated. Some of
the signal transduction molecules include Src family tyrosine kinases, Grb2, phosphatidylinositol
3-kinase (PI3K), phospholipase C-y (PLC-y), and GTPase activating protein (GAP) for Ras
(Claesson-Welsh, 1996; Heldin, 2013). Receptors also bind signal transducers and activators of
transcription (STATs) which translocate to the nucleus to act as transcription factors (Heldin,
2013). The activation of these signaling pathways leads to cell proliferation and survival, as well
as cell migration.
In the CNS, PDGFRa is expressed on oligodendrocyte precursor cells (OPCs), which are
a distinct glial cell type capable of differentiating into oligodendrocytes or astrocytes (Jackson et
al., 2006). Not all OPCs differentiate, so a population of OPCs remains proliferative throughout
life (Dawson et al., 2003). OPCs are the major source for oligodendrocytes, which are the cells
that form the myelin sheath around neuronal axons for rapid neuron firing (Zhu et al., 2008).
Survival and proliferation of OPCs is dependent on PDGF signaling (Calver et al., 1998). PDGFAA is produced by neurons and astrocytes (Raff et al., 1988). PDGF-AA signaling maintains
OPCs in a proliferative and undifferentiated state, and is important for the timing of
oligodendrocyte development (Raff et al., 1988; Erlandsson et al., 2001; Vela et al., 2002). It has
been shown that withdrawal of PDGF-AA from culture medium is sufficient to cause OPC
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differentiation (Raff et al., 1988). PDGFRa is rapidly downregulated when OPCs begin to
differentiate (Hart, 1989). PDGFRa is also expressed in some neural stem cells, which are cells
found primarily in the subventricular zone that can self-renew and differentiate into multiple cell
lines even in adulthood (Jackson et al., 2006; Reynolds and Weiss, 1992). PDGF signaling leads
to the proliferation of these neural stem cells as well as induces them to enter oligodendrocyte
lineage rather than neuronal lineage (Erlandsson et al., 2001; Menn et al., 2006).
There is significant evidence that overexpression or hyperactivity of PDGF ligands and
receptors is a cause of gliomas. Activation of PDGF signaling pathways has been observed in
more than 80% of oligodendrogliomas and in 50-100% of astrocytomas (Guha et al., 1995;
Varela et al., 2004). Guha et al. compared glioma specimens of varying grades to non-neoplastic
glial specimens (1995). They found that PDGF-A, PDGF-B, and PDGFRa were all more highly
expressed in glioma than the non-neoplastic glial specimens (1995). The levels of PDGF-A, and
PDGF-B, and PDGFRa were all slightly more elevated in the higher grades of glioma compared
to the lower grades (Guha et al., 1995). Another analysis of human glioma tissue samples
similarly revealed that PDGF ligands and PDGFRa were overexpressed in all grades of gliomas,
but were found at the highest levels in glioblastoma (Hermanson et al., 1992; Hermanson et al.,
1996). Another study found that the level of PDGFRa may be associated with malignancy of the
tumor: amplification of PDGFRa was detected in 0% of Grade II tumors, 3.6% of Grade III
tumors, and 9.15% of Grade IV tumors (Alentorn et al., 2012). Due to both PDGF ligand and
PDGFRa overexpression together, it is likely that autocrine and paracrine loops are involved in
activating this growth pathway and may be the reason for the uncontrolled growth of these
tumors (Guha et al., 1995; Hermanson et al., 1996). Activation of these loops may be an early
event in glioma development because PDGF and PDGFRa overexpression is observed even in
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the low grades of glioma. These PDGF signaling loops may also be involved in tumor
progression, because the highest expression is seen in the most severe grades.
Efforts to induce gliomas also revealed the role of PDGF signaling in glioma
development. A retrovirus encoding PDGF-B was injected into newborn mice and resulted in
highly malignant gliomas (Uhrbom et al., 1998). All of the tumors were found to express PDGFB and PDGFRa mRNA, but not PDGFRb (Uhrbom et al., 1998). Since PDGF-B is a high affinity
ligand for PDGFRa, this is more evidence of an autocrine pathway that leads to glioma
development. A similar experiment was conducted where a retrovirus encoding PDGF-B was
injected into the subcortical white matter of adult rats. 100% of the rats developed tumors that
had similar characteristics to glioblastoma (Assanah et al., 2006). They found that the retrovirus
predominantly infected OPCs, but most of the proliferating cells were uninfected OPCs that were
recruited by paracrine signaling by PDGF-A and B that was secreted by the glioma cells
(Assanah et al., 2006). Experiments that infused PDGF-A into the subventricular zone led to the
proliferation of PDGFRα expressing neural stem cells that formed glioma like lesions (Jackson et
al.,2006). It has also been shown that overexpressing PDGF leads to the proliferation of OPCs
that can result in oligodendroglioma-like lesions in mice (Appolloni et al., 2009; Dai et al.,
2001).
These findings suggest that blocking the activity of the tyrosine kinase portion of the
receptor would reduce PDGF signaling and therefore reduce the proliferation of glioma cells.
However, tyrosine kinase inhibitors (TKIs) that are currently in clinical trials have been
ineffective when given to glioma patients (Nazarenko et al., 2012). These agents have had
response rates of only 0-15% and no prolongation of 6-month progression free survival (Wen
and Kesari, 2008). Small molecule TKIs, like imatinib, sunitinib, and sorafenib, are thought to be
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ineffective because they are non-specific inhibitors of multiple kinases with lower potency for
PDGFR, and also because resistant mutations of PDGFR often arise that prevent binding of the
drugs (Heldin, 2013).
Although inhibition of PDGFR kinase activity has been unsuccessful, decreasing this
signaling pathway though other mechanisms could be an alternate path for inhibiting glioma cell
proliferation. An initial screen previously conducted by the Nishiyama lab led to identification of
small molecule compounds that inhibit PDGFRa transcription (Medved, 2014). Some of the
compounds that were found to downregulate PDGFRa had similar chemical structures based on
N-methyl-N-benzylguanidine structure (guanidine compound). 12 guanidine derivatives were
synthesized by the Wright lab for further investigation. These derivatives were found to have
differing effects on PDGFRa transcription, as seen through luciferase assay and qPCR (Medved,
2014). DW002, DW003, DW004, DW005, DW007, DW008 significantly decreased PDGFRa
transcription, while DW001, DW006, DW009, DW0010, DW0011, and DW0012 did not have a
significant effect (Figure 1).

A

B

Figure 1. Guanidine derivative compounds have different effects on PDGFRa transcription. A) Oli-neu cells were
treated with 3 uM or 30 uM of 12 different guanidine derivative compounds for 2 days. A luciferase assay was
conducted to measure PDGFRa transcription. 30 uM of DW002 and DW008 caused the greatest downregulation
of PDGFRa. Data is presented as relative to DMSO control (100%). B) mRNA was collected from Oli-neu cells
treated with five different guanidine derivative compounds and PDGFRa transcription was analyzed by qPCR. The
results reflect the luciferase assay results. DW002 and DW008 cause a robust decrease in PDGFRa transcription,
while DW006 and DW012 do not. dCtC = delta Ct of DMSO control; dCtT = delta Ct. Bars represent average result
obtained from 3 independent experiments. Error bars are standard errors of the mean. * p < 0.05, one sample ttest. (Modified from Medved, 2014).
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As previously discussed, increased signaling through PDGFRa and its overexpression is a
common event involved in the pathology of glioma formation. Therefore, these compounds that
were found to decrease transcription of PDGFRa are interesting because they could limit
PDGFRa signaling and possibly have a therapeutic effect in glioma. I have chosen to focus in
depth on two of the guanidine derivatives tested: DW002 and DW006. DW002 caused the most
robust decrease in PDGFRa transcription while DW006 did not have a significant effect.
However, these compounds only differ in the placement of a methoxy group on the benzyl ring
(Figure 2). Discovering the mechanism that leads to their different outcomes could help us to
find a pathway that leads to downregulation of PDGFRa.

Figure 2. Chemical structures of compounds of interest. The chemical structure of DW002 (left) and
DW006 (right) differ by the placement of the methoxy group on the aromatic ring (indicated by box).

In this project, I have conducted cell viability and cytotoxicity assays to determine if
DW002 leads to decreased cell proliferation without causing cell death. I also used qPCR to
determine if the compounds are specifically targeting PDGFRa transcription and not PDGFRb
transcription. To investigate the mechanism by which DW002 may work, I have treated the cells
with kinase inhibitors to block different signaling pathways. This was also explored by iTRAQ
(isobaric tags for relative and absolute quantification) analysis, a proteomics technology that will
allow us to compare protein expression of samples treated with each compound.
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Materials and Methods
Cell culture
Oli-neu cells were used as a model for OPCs. Oli-neu cells are derived from primary
murine OPCs that have been transformed with an ErbB2 oncogene, t-neu (Jung et al., 1995). Cell
culture dishes were coated with 30 ug/ml polylysine solution prior to plating cells. Cells were
grown in Dulbecco’s Modified Eagle’s Medium (DMEM)/F12 medium containing 1% N2
supplement, 1% horse serum, 1X penicillin/streptomycin, and 1X glutamine. Cells were kept at
37C with 5% CO2. When the cells became ~80% confluent, they were split by trypsinization.

DW002 and DW006 compounds
DW002 and DW006 were synthesized by the Wright lab and provided to us as a 50 mM
stock dissolved in dimethyl sulfoxide (DMSO).

Cell viability assay
Cells were plated in triplicate at 10,000 cells/well in a 96-well white plate and incubated
overnight. Cells were also plated at the same time in triplicate in a clear plate. Cells in both
plates were then treated with DW002 or DW006 for two days. Cell viability was determined
using the Cell Titer Glo 2.0 Assay (Promega) according to the manufacturer’s protocol. In
addition to the assay, cell morphology changes were visualized under light microscope using the
cells in the clear plate. The concentration of compound that inhibited 50% of cell viability (IC50)
was calculated with GraphPad Prism 6 using the equation: Y=Bottom + (TopBottom)/(1+10^((LogIC50-X)*HillSlope)). Statistical significance of a difference between
DW002 and DW006 was determined using an unpaired Student’s t-test for each concentration.
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Since the DMSO control of the previous experiment appeared to significantly decrease
cell viability, a DMSO assay was conducted to determine the effects of the DMSO that the
compounds were dissolved in. Cells were plated in triplicate at 10,000 cells/well in a 96-well
white plate and incubated overnight. Cells were then treated with concentrations of DMSO that
corresponded to the amount of DMSO added with each of the treatments with DW002 and
DW006. The Cell Titer Glo 2.0 Assay was conducted according to the manufacturer’s protocol
after two days of treatment.

Cytotoxicity assay
Cells were plated in triplicate in horse serum free medium at 10,000 cells/well in a 96well black plate as well as a 96-well clear plate and incubated overnight. Cells in both plates
were then treated with digitonin, lysis buffer, DW002, and DW006 for one or two days. Cell
death was measured using the CellTox Green Cytotoxicity Assay (Promega) according to the
manufacturer’s protocol for cells in the black plate. Cells in the clear plate were also visualized
under a light microscope to observe morphological changes.

Quantitative PCR (qPCR)
mRNA was previously collected from Oli-neu cells treated with DMSO control, 50 uM
DW002, and 50 uM DW006 for two days and converted to cDNA. Three independent sample
sets were analyzed, each in triplicate. Reactions were prepared with 100 ng cDNA, 3 uM of
primers, and SsoAdvanced Universal SYBR Green Supermix for a total reaction volume of 20
ul. PDGFRb and GAPDH primers were used (in table below). The data is expressed as raw Cq
values, as well as normalized to GAPDH.
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Gene

Forward primer

Reverse primer

PDGFRb

CACCTTCTCCAGTGTGCTGAC CGGAGTCCATAGGGAGGAAG

GAPDH

TGACAACTTTGGCATTGTGG

ATGCAGGGATGATGTTCTGG

iTRAQ optimization
In preparation for iTRAQ analysis, a series of experiments were conducted to determine
the best practice for plating the cells in serum free medium (SFM). SFM is DMEM/F12 medium
containing 1% N2 supplement, 1X penicillin/streptomycin, and 1X glutamine. Cells were plated
in triplicate at 100,000 cells/well in a 24-well clear plate in serum-containing medium. The
medium was changed to SFM at three different times: upon plating, 2 hours post plating, and 24
hours post plating. Phase contrast pictures were taken one, two, and three days after plating.
Next, cells were plated in triplicate at 10,000 cells/well in a 96-well white plate, switched
to SFM two hours after plating, and incubated overnight. Cells were treated with DW002 +/PDGF growth factor for two days. Cell viability was determined using the Cell Titer Glo 2.0
Assay according to the manufacturer’s protocol.
After determining the conditions for sample preparation, the cell samples were prepared.
Four different samples were prepared in four different 10 cm plates. 4x106-5x106 cells were
plated in each plate, medium was changed to SFM after two hours, and then incubated overnight.
Each plate of cells received a different treatment: DMSO control (0.2%) incubated for 20 hours,
30 uM 002 incubated for 20 hours, 30 uM DW006 incubated for 20 hours, or 30 uM DW002
incubated for 30 hours. Cells were harvested from the plates and snap-frozen in liquid nitrogen.
This was repeated to create an identical set of plates. Eight samples were generated (four
treatments in duplicate). The frozen samples were sent to the Beth Israel Deaconess Medical
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Center Proteomics Center and Dana Farber/Harvard Cancer Center Cancer Proteomics Core for
iTRAQ analysis.
Data from iTRAQ analysis was reported as ratios between the different treatments for
each protein. 245 proteins were analyzed. The ratios of interest were identified (114:113,
118:117, 116:113, 121:117, 115:113, 119:117, 114:115, and 118:119). For each list of ratios
between two treatments, GraphPad Prism 6 was used to calculate the 25th and 75th percentile.
These cut offs were used to flag proteins as “abnormal”. Protein “hits,” meaning proteins that
were more or less expressed after DW002 treatment, were identified in two ways. In Method 1,
proteins were classified as hits if they were abnormal after both short and long incubations with
DW002, but not with DW006. In Method 2, proteins were classified as hits if they were
abnormal for both replicates of DW002:DW006. They were classified as strong hits if the ratios
for both replicates were <0.5 or >2 (arbitrarily chosen).

Inhibitor treatment
Inhibitor compounds were purchased from SelleckChem and dissolved in DMSO to
obtain 50 mM stock solutions. 10 fold dilutions of the 50 mM were created to make additional
stocks. Cells were plated in triplicate at 10,000 cells/well in a 96-well white plate and incubated
overnight. Cells were treated with inhibitors of p38 MAP kinase (SB202190), JNK (SP600125),
PI3K (LY294002), and PDGFRa (ponatinib, axitinib) for two days +/- DW002. Inhibitors +/DW002 were diluted in medium then added to the cells to obtain the correct final concentrations.
Cell viability was then measured using Cell Titer Glo 2.0 Assay.
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Results
DW002 has a more potent effect on cell viability than DW006
We first wanted to determine if the compounds had different effects on cell proliferation,
so dose response was evaluated using a cell viability assay. Oli-neu cells were plated in a 96-well
plate and allowed to adhere overnight. The next day, cells were treated with 10-fold dilutions of
DW002 and DW006 ranging from 0.1 uM to 1000 uM and incubated for two days before
conducting the Cell Titer Glo 2.0 Assay (Figure 3A). DW002 and DW006 had differing effects
on cell viability that can be seen visually on the graph. At lower concentrations, neither DW002
nor DW006 appeared to affect cell viability, but DW002 appeared to have an effect at a lower
concentration than DW006. At higher concentrations, DW002 appeared to be associated with a
greater decrease in cell viability than DW006. The difference in effect between DW002 and
DW006 was analyzed using an unpaired Student’s t-test for each concentration. It was found that
the compounds had a statistically different effect on cell viability at 100 uM.
From the initial dose response assay, we noticed the strong decrease in cell viability that
occurred with the DMSO control. The DMSO control was 2% DMSO, which was the highest
concentration of DMSO added to the cells due to the compounds being dissolved in DMSO.
When the cells were viewed under the light microscope, the DMSO seemed to have a cytotoxic
effect. Cells were rounded and less adherent to the plate, indicating cell death. We wanted to
ensure that the effect seen due to the compounds was not due to the DMSO that they were
dissolved in. Therefore, the cell viability assay was conducted again, but this time cells were
treated with DMSO concentrations that corresponded to the amount added with each compound
treatment (Figure 3B). From the results, it can be seen that DMSO did not have a toxic effect on
the cells expect at the highest concentration of 2%, which was the amount added when cells were
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treated with 1000 uM of compound. Therefore, it is reasonable to think that the effects seen at
lower concentrations are due to the compound itself rather than DMSO toxicity.
To further explore the dose dependent effects of the compounds, we next focused on a
more narrow concentration range. Cells were again plated in triplicate in a 96-well plate and
incubated overnight. The next day, the cells were treated with 3-fold dilutions of DW002 and
DW006 ranging from 1 uM to 300 uM. After two days, cell viability was analyzed (Figure 3C).
It can be seen that DW002 has a more potent effect than DW006. DW002 is associated with a
dose dependent decrease in cell viability, whereas DW006 does not show a strong dosedependent effect at these concentrations. The data was analyzed using an unpaired Student’s ttest for each concentration. There is a statistically significant difference in effect for 10, 30, 100,
and 300 uM. The most significant difference between the two compounds was at 100 uM
(p<0.0001, unpaired Student’s t-test). Dose response curves were created and the IC50 was
determined using GraphPad Prism 6 (Figure 3D). The IC50 for DW002 is much lower than
DW006, indicating that it has a more potent effect on cell viability.
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Figure 3. DW002 decreases cell viability in a dose dependent manner not exhibited by DW006. A) Cells were
treated with increasing concentrations (0.1-1000 uM) of DW002 and DW006 for 2 days. DMSO control = 2%
DMSO, corresponding to the largest amount of DMSO added with the compounds. Cell viability was measured
with Cell Titer Glo 2.0 Assay. Luminescence corresponds to the number of viable cells. It can be visually seen that
DW002 and DW006 differ in their effect on cell viability. There is a statistically significant difference in effect for
100 uM and 1000 uM (**, P<0.001; unpaired Student’s t-test). B) Cells were treated with DMSO concentrations
corresponding to the compound treatments in A. The data in B confirms that the effect on cell viability was due
to the compounds except for the highest concentration (1000 uM). C) Cells were treated with increasing
concentrations (1-300 uM) of DW002 and DW006 for 2 days. This range expanded a narrow section of
concentrations from A (red box). Cell viability was measured with Cell Titer Glo 2.0 Assay. Luminescence
corresponds to the number of viable cells. It can be visually seen that DW002 has a more potent effect on cell
viability than DW006. There is a statistically significant difference in effect for the higher concentrations (*,
P<0.05; **, P<0.001; ***, P<0.0001; unpaired Student’s t-test). D) Effect of DW002 and DW006 on cell viability
expressed as percent of control (0 uM). The IC50 of DW002 is 15.62 uM and the IC50 of DW006 is 82.38 uM.
Fitted curves were generated using 4-parameter nonlinear regression. Data represent means of the triplicates
and error bars represent standard deviation.
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DW002 and DW006 did not cause increased cell death
After determining that the compounds did decrease cell viability, the next goal was to
determine if this effect was due to a cytotoxic property of the compounds or whether they were
inhibiting proliferation. To investigate this, we conducted a cell toxicity assay. Cells were plated
in a 96-well black plate and incubated overnight. The next day, cells were treated with lysis
buffer, digitonin, and 100 uM of DW002 and DW006. Cell death was measured after one and
two days (Figure 4). Cell death upon treatment with either compound is comparable to untreated
cells (control). This indicates that the compounds have minimal cytotoxic effect.
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DW006
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DW002

DW006

Treatment

Figure 4. DW002 and DW006 do not cause increased cell death after 24 hours or 48 hours of treatment. A)
Cells were treated with 100 uM of DW002 and DW006 for one day. B) Cells were treated with 100 uM of
DW002 and DW006 for two days. In both A and B, cell death was measured using the CellTox Green
Cytotoxicity Assay. Fluorescence corresponds to the number of dead cells. Digitonin (30 ug/ml) and lysis buffer
(1:25) were used as positive controls for cell death. Control = untreated cells. Bar graph values represent
means of the triplicates and error bars represent standard deviation.
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DW002 is selective for PDGFRa over PDGFRb
Previous research conducted by Jelena showed that DW002 and related compounds
decreased transcription of PDGFRa. PDGFRa and PDGFRb are structurally very similar but
have very different physiologic functions. Therefore, our next goal was to determine if DW002
decreased transcription of both PDGFRs or just PDGFRa. To examine this, qPCR was conducted
using cDNA samples taken from the same cells that Jelena studied. There were three different
treatments analyzed: untreated, 50 uM DW002, or 50 uM DW006. Of each treatment, there were
three independent samples. Astrocytes are known to express PDGFRb, so cDNA from cultured
astrocytes were used as a positive control. GAPDH was used as an internal control. 100 ng of
cDNA was used with 3 uM of each primer. qPCR was run in triplicate. From the graph of the Cq
results, it does not appear that the compounds change the transcription of PDGFRb in
comparison to the control (Figure 5). It is important to note however that the results show that
the average Cq value for the astrocyte samples was 22.92, while the average Cq value for the
control Oli-neu samples was 35.15. This indicates that the expression of PDGFRb in Oli-neu
cells is very low. Therefore, it is difficult to detect any effect that the compounds may have on
PDGFRb transcription. However, since PDGFRb is not expressed in Oli-neu cells, we can be
fairly confident that the effect of the compounds is specific to PDGFRa and that the results so far
were not confounded by acting on PDGFRb.

Cq PDGFRb/Cq GAPDH
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Figure 5. PDGFRb is not expressed in Oli-neu cells. mRNA was collected from astrocytes, Oli-neu cells
treated with DMSO control, and Oli-neu cells treated with 50 uM DW002 or DW006 for two days, and
converted to cDNA. The cDNA samples were analyzed by qPCR to detect if the compounds affected
PDGFRb expression. The Cq values are expressed as normalized to GAPDH (A) as well as the raw values
(B). By comparing the Cq values to the positive control (astrocytes), we concluded that PDGFRb is not
expressed in Oli-neu cells. Therefore, the effect of DW002 and DW006 on Oli-neu cells is likely due to its
effect on PDGFRa transcription. Bar graph values represent means of the triplicates and error bars
represent standard deviation.
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DW002 maintains its activity in serum free medium
We next wanted to determine the mechanism by which DW002 was able to decrease
PDGFRa transcription, because this appeared to be linked to its activity of inhibiting cell
proliferation. To investigate this, we decided to utilize iTRAQ analysis, a proteomics technology.
This method labels all of the protein in a sample with an isobaric tag, and then determines the
amount and the identity of the proteins in the sample through mass spectrometry. Different tags
allows for the comparison of different samples. The samples that we chose to compare were:
DMSO control, 30 uM DW002, 30 uM DW006, and 30 uM DW002 after a longer incubation.
iTRAQ is more effective for serum free samples, so before preparing the previously
mentioned samples, we had to confirm that the Oli-neu cells would survive and that the activity
of DW002 remained unchanged in SFM. To test this, I plated cells in triplicate in a 24-well plate
and switched to SFM at different times to determine the best conditions for the cells. I switched
the medium upon plating, 2 hours post plating, and 24 hours post plating. I took phase contrast
pictures one, two, and three days after plating the cells and compared them to the cells in regular
medium (Figure 6). Cells plated immediately in serum free medium survived for one day but
then seemed to decline, evident from the clumped appearance. Cells in SFM two hours after
plating appeared to survive and increase in density each day, suggesting that they were able to
proliferate normally, although they did not reach the same density as the cells in regular medium.
They also remained adherent to the plate and extended processes. Cells in SFM 24 hours after
plating also increased in density and extended processes, indicating they were healthy and
proliferative. I chose to proceed with the iTRAQ sample preparations by changing the medium
of the Oli-neu cells to SFM two hours after plating.
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Figure 6. Oli-neu cells survive and proliferate when switched to SFM 2 or 24 hours after plating. Oli –neu
cells were plated under different conditions (A-D) and phase contrast pictures were taken 1, 2, and 3 days
after plating. A) Cells were plated in regular medium and used as a control. The cells proliferated rapidly. B)
Cells were plated in regular medium and switched to SFM after 24 hours. These cells appeared healthy and
proliferated to about the same extent as the control cells. C) Cells were plated in regular medium and switch
to SFM after 2 hours. These cells also appeared healthy and proliferated quickly. D) Cells were plated
immediately in SFM. These cells did not appear as healthy as the other treatments. They clumped together
and did not adhere well to the plate, indicating cell death.
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Next I confirmed that DW002 maintained its activity by conducting the cell viability
assay again. Cells were plated in triplicate in a 96-well plate and medium was changed to SFM
two hours later. The cells were incubated overnight. The next day they were treated with DMSO
control (0.2%), 100 uM DW002, 20 ng/ml PDGF, and 100 uM DW002 + 20 ng/ml PDGF. Cell
viability was measured after two days. It can be seen that DW002 still decreases cell
proliferation in SFM (Figure 7). Of additional interest, it can be seen that DW002 maintains this
effect even in the presence of the growth factor PDGF. However, PDGF did not lead to a strong
increase in cell proliferation.
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Figure 7. DW002 maintains its effect on cell viability under serum-free conditions. Cells in
SFM were treated with 100 uM DW002 +/- 20 ng/ml PDGF. DW002 still decreased cell
viability in SFM, even in the presence of growth factor. Control = untreated cells, DMSO
control = 0.2% DMSO. Bar graph values represent means of the triplicates and error bars
represent standard deviation.
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After confirming that the cells would survive and that DW002 effect could still be
observed in SFM, the four different samples (in duplicate) were sent for iTRAQ analysis. 245
proteins were analyzed. The iTRAQ data was reported back to us as ratios between samples,
which allowed us to identify proteins that were more or less expressed in one treatment
compared to another. Proteins were expressed at the same level if the ratio was 1. The samples
were labeled as follows: DMSO control was 113 and 117, 30 uM DW002 short incubation was
114 and 118, 30 uM DW006 was 115 and 119, and 30 uM DW002 long incubation was 116 and
121. Before comparing any proteins, I first determined if the data was normally distributed. From
analysis with GraphPad Prism 6, I found that the data was not normally distributed. Therefore, I
calculated the 25th and 75th percentile for each ratio. I used these values as cut off points to
classify a protein as being more (>75th percentile) or less (<25th percentile) expressed, which I
will call “abnormal”.
The data was analyzed in two ways to find proteins whose expression may be altered by
DW002 treatment. Because samples were taken at two different times after treatment with
DW002, I wanted to determine if there were any proteins that were consistently abnormal at both
times compared to control, that were unchanged when treated with DW006. Therefore, I focused
on the ratios: 114:113, 118:117, 116:113, 121:117, 115:113, and 119:117. I flagged proteins as
“hits” if protein ratios were abnormal for 114:113, 118:117, 116:113, 121:117, but not 115:113
and 119:117. From this method (Method 1), I identified 6 hits (Table 1). Three of these proteins
were more expressed, and three were less expressed. The second method (Method 2) that I used
to analyze the data was to focus directly on the ratios between DW002 and DW006, which were
114:115 and 118:119. I flagged proteins as hits if they had abnormal expression in both
replicates. I identified 34 proteins using this method (Table 1). Of these, 17 were more expressed
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and 17 were less expressed. Because of the relatively large number of proteins I identified as
hits, I attempted to find the most important proteins by identifying what I will call “strong hits.” I
defined this as protein ratios <0.5 or >2, which were values arbitrarily chosen. I identified 6
strong hits, 2 that were more expressed and 4 that were less expressed. I used UniProt to find the
function of proteins found to be hits using Method 1 and strong hits using Method 2. The
descriptions of the proteins from UniProt are listed in Table 2.
Of the 6 hits I identified from Method 1, 5 were also hits identified by Method 2.
However, only 2 of the hits identified from Method 1 were also strong hits under Method 2. This
is summarized in Figure 8. From analysis using Method 1, I did not identify any proteins that
were abnormal at the longer incubation with DW002 but not at the short incubation, which may
indicate that protein changes occur early after treatment with DW002.
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Method 1
Method 2
Alpha-enolase OS=Mus musculus GN=Eno1 PE=1
Heat shock cognate 71 kDa protein OS=Mus musculus GN=Hspa8 PE=1 SV=1
SV=3
Acyl-CoA-binding protein OS=Mus musculus
Alpha-enolase OS=Mus musculus GN=Eno1 PE=1 SV=3
GN=Dbi PE=1 SV=2
40S ribosomal protein S19 OS=Mus musculus
Heterogeneous nuclear ribonucleoproteins A2/B1 OS=Mus musculus
GN=Rps19 PE=1 SV=3
GN=Hnrnpa2b1 PE=1 SV=2
Ubiquitin-40S ribosomal protein S27a OS=Mus
Tropomyosin alpha-3 chain OS=Mus musculus GN=Tpm3 PE=1 SV=1
musculus GN=Rps27a PE=1 SV=2
Calmodulin OS=Mus musculus GN=Calm1 PE=1
Acyl-CoA-binding protein OS=Mus musculus GN=Dbi PE=1 SV=2
SV=1
Histone H4 OS=Mus musculus GN=Hist1h4a PE=1 Glyceraldehyde-3-phosphate dehydrogenase OS=Mus musculus GN=Gapdh
SV=2
PE=1 SV=1
Pyruvate kinase PKM OS=Mus musculus GN=Pkm PE=1 SV=4
Nuclease-sensitive element-binding protein 1 OS=Mus musculus GN=Ybx1
PE=1 SV=3
40S ribosomal protein S19 OS=Mus musculus GN=Rps19 PE=1 SV=3
Elongation factor 1-alpha 1 OS=Mus musculus GN=Eef1a1 PE=1 SV=3
Ubiquitin-40S ribosomal protein S27a OS=Mus musculus GN=Rps27a PE=1
SV=2
40S ribosomal protein S3 OS=Mus musculus GN=Rps3 PE=1 SV=1
Adenosylhomocysteinase OS=Mus musculus GN=Ahcy PE=1 SV=3
Isoform 2 of Heterogeneous nuclear ribonucleoprotein K OS=Mus musculus
GN=Hnrnpk
ATP synthase subunit delta, mitochondrial OS=Mus musculus GN=Atp5d
PE=1 SV=1
Isoform 4 of Hepatoma-derived growth factor-related protein 2 OS=Mus
musculus GN=Hdgfrp2
Isoaspartyl peptidase/L-asparaginase OS=Mus musculus GN=Asrgl1 PE=1
SV=1
Histone H4 OS=Mus musculus GN=Hist1h4a PE=1 SV=2
G7b alternative form OS=Mus musculus GN=Lsm2 PE=1 SV=1
Short-chain specific acyl-CoA dehydrogenase, mitochondrial OS=Mus
musculus GN=Acads PE=1 SV=2
Putative mitochondrial import inner membrane translocase subunit Tim8 A-B
OS=Mus musculus GN=Timm8a2 PE=3 SV=1
Cell adhesion molecule 4 OS=Mus musculus GN=Cadm4 PE=1 SV=1
Phytanoyl-CoA hydroxylase-interacting protein OS=Mus musculus GN=Phyhip
PE=1 SV=1
40S ribosomal protein S13 OS=Mus musculus GN=Rps13 PE=1 SV=2
Putative RNA-binding protein Luc7-like 2 OS=Mus musculus GN=Luc7l2 PE=1
SV=1
Isoform Short of Cyclin-dependent kinase 16 OS=Mus musculus GN=Cdk16
Protocadherin Fat 3 OS=Mus musculus GN=Fat3 PE=1 SV=1
N-acetylglucosamine-6-sulfatase OS=Mus musculus GN=Gns PE=2 SV=1
Protein Vmn1r204 OS=Mus musculus GN=Vmn1r204 PE=4 SV=1
FH2 domain-containing protein 1 OS=Mus musculus GN=Fhdc1 PE=2 SV=3
Guanylate cyclase OS=Mus musculus GN=Gucy2d PE=3 SV=1
Molybdopterin synthase catalytic subunit OS=Mus musculus GN=Mocs2 PE=2
SV=3
Notchless protein homolog 1 OS=Mus musculus GN=Nle1 PE=1 SV=4
Opioid growth factor receptor OS=Mus musculus GN=Ogfr PE=2 SV=1
6
34
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Table 1. Expression of certain proteins was altered after treatment with DW002 but not DW006. iTRAQ
analyzed expression of 245 proteins. Ratios were calculated between each treatment (DMSO control, 30 uM
DW002 short incubation, 30 uM DW006 short incubation, and 30 uM DW002 long incubation). In Method 1,
ratios between DW002 and control and DW006 and control were analyzed. Proteins were identified as hits if
th

they were in the bottom or top 25 percentile after treatment with DW002 (at both incubation times) but not
treatment with DW006. Six proteins were hits using this method. In Method 2, ratios between DW002 and
th

DW006 were analyzed. Proteins were identified as hits if they were in the bottom or top 25 percentile, and
strong hits if ratios were <0.5 or >2. Using the method, 34 proteins were hits and 6 were strong hits. Bolded
protein names are those found using both methods. Blue = more expressed, orange = less expressed. For
Method 2, the dark blue and orange represent strong hits.

Method 2
Method 1

25

3
4

1

2

Figure 8. Method 1 and Method 2 of iTRAQ data analysis identified some of the same and
some different protein hits. The purple circle represents protein hits found using Method 1,
the green circle represents hits found by Method 2, and the yellow circle represent hits
found by Method 1. 5 of the 6 hits found by Method 1 were also identified using Method 2. 2
of the 6 hits from Method 1 were strong hits identified by Method 2.
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Alpha-enolase

Acyl-CoA-binding protein
40S ribosomal protein S19

Ubiquitin-40S ribosomal
protein S27a

Calmodulin

Histone H4

Pyruvate kinase PKM

Adenosylhomocysteinase

Isoform 2 of Heterogeneous
nuclear ribonucleoprotein K

Molybdopterin synthase
catalytic subunit

Multifunctional enzyme that, as well as its role in glycolysis, plays a part in various processes
such as growth control, hypoxia tolerance and allergic responses. May also function in the
intravascular and pericellular fibrinolytic system due to its ability to serve as a receptor and
activator of plasminogen on the cell surface of several cell-types such as leukocytes and
neurons. Stimulates immunoglobulin production.
Binds medium- and long-chain acyl-CoA esters with very high affinity and may function as an
intracellular carrier of acyl-CoA esters. It is also able to displace diazepam from the
benzodiazepine (BZD) recognition site located on the GABA type A receptor. It is therefore
possible that this protein also acts as a neuropeptide to modulate the action of the GABA
receptor.
Required for pre-rRNA processing and maturation of 40S ribosomal subunits.
Ubiquitin: Exists either covalently attached to another protein, or free (unanchored).
Polyubiquitin chains, when attached to a target protein, have different functions depending on
the Lys residue of the ubiquitin that is linked: Lys-6-linked may be involved in DNA repair; Lys11-linked is involved in ERAD (endoplasmic reticulum-associated degradation) and in cell-cycle
regulation; Lys-29-linked is involved in lysosomal degradation; Lys-33-linked is involved in kinase
modification; Lys-48-linked is involved in protein degradation via the proteasome; Lys-63-linked
is involved in endocytosis, DNA-damage responses as well as in signaling processes leading to
activation of the transcription factor NF-kappa-B.
Calmodulin mediates the control of a large number of enzymes, ion channels, aquaporins and
other proteins by Ca2+. Among the enzymes to be stimulated by the calmodulin-Ca2+ complex
are a number of protein kinases and phosphatases.
Core component of nucleosome. Nucleosomes wrap and compact DNA into chromatin, limiting
DNA accessibility to the cellular machineries which require DNA as a template. Histones thereby
play a central role in transcription regulation, DNA repair, DNA replication and chromosomal
stability. DNA accessibility is regulated via a complex set of post-translational modifications of
histones, also called histone code, and nucleosome remodeling.
Glycolytic enzyme that catalyzes the transfer of a phosphoryl group from phosphoenolpyruvate
(PEP) to ADP, generating ATP. Stimulates POU5F1-mediated transcriptional activation. Plays a
general role in caspase independent cell death of tumor cells. The ratio betwween the highly
active tetrameric form and nearly inactive dimeric form determines whether glucose carbons
are channeled to biosynthetic processes or used for glycolytic ATP production. The transition
between the 2 forms contributes to the control of glycolysis and is important for tumor cell
proliferation and survival.
Adenosylhomocysteine is a competitive inhibitor of S-adenosyl-L-methionine-dependent methyl
transferase reactions; therefore adenosylhomocysteinase may play a key role in the control of
methylations via regulation of the intracellular concentration of adenosylhomocysteine
One of the major pre-mRNA-binding proteins. Binds tenaciously to poly(C) sequences. Likely to
play a role in the nuclear metabolism of hnRNAs, particularly for pre-mRNAs that contain
cytidine-rich sequences. Can also bind poly(C) single-stranded DNA. Plays an important role in
p53/TP53 response to DNA damage, acting at the level of both transcription activation and
repression. When sumoylated, acts as a transcriptional coactivator of p53/TP53, playing a role in
p21/CDKN1A and 14-3-3 sigma/SFN induction (By similarity). As far as transcription repression is
concerned, acts by interacting with long intergenic RNA p21 (lincRNA-p21), a non-coding RNA
induced by p53/TP53. This interaction is necessary for the induction of apoptosis, but not cell
cycle arrest.
Catalytic subunit of the molybdopterin synthase complex, a complex that catalyzes the
conversion of precursor Z into molybdopterin. Biosynthesis of molybdopterin, an essential
cofactor for the catalytic activity of some enzymes, e.g. sulfite oxidase, xanthine dehydrogenase,
and aldehyde oxidase.

Table 2. Functions of protein hits identified by Method 1 and strong hits identified by Method 2. Expression of
these proteins were found to be altered after treatment with DW002. The methods that were used to identify
these proteins have been previously explained. The functions of these proteins was identified using UniProt
(www.uniprot.org). Bolded protein names were found using both methods. Blue = more expressed, orange = less
expressed. Dark blue and orange represent strong hits.
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Inhibition of specific intracellular signaling pathways did not change the effect of DW002
While iTRAQ analysis was being conducted, we explored the mechanism of DW002 by
inhibiting intracellular signaling pathways. We hypothesized that if inhibition of a signaling
pathway eliminated the effect of DW002, DW002 may be altering that pathway in some way to
decrease PDGFRa transcription. Cells were plated in triplicate in a 96-well plate and incubated
overnight. They were then treated with a wide range of concentrations of inhibitors for various
kinases or receptors, with or without DW002. The various inhibitors blocked: p38 MAP kinase
(SB202190), JNK (SP600125), PI3K (LY294002), and PDGFRa (ponatinib, axitinib). The
concentrations of the inhibitors were based off of their reported IC50 values. Cell viability was
measured after two days. None of the inhibitors blocked the effect of DW002 (Figure 9). DW002
retained its ability to decrease cell proliferation even in the presence of inhibitors that blocked
many major signal transduction pathways. Another interesting result was that inhibition of
PDGFRa did not inhibit cell proliferation, even though blocking PDGFRa in OPCs would be
expected to have that effect.
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Figure 9. Treatment with inhibitors does not block the effect of DW002. Cells were treated with increasing
concentrations of potent and selective inhibitors with or without 30 uM of DW002 for 48 hours. Cell viability was
measured using the Cell Titer Glo 2.0 Assay. Luminescence corresponds to the number of viable cells. If DW002
acted through the pathway blocked by the inhibitor, we would expect to DW002 to no longer decrease cell
viability. Treatment with p38 mitogen activated protein kinase (MAPK) inhibitor (A), c-Jun N-terminal kinase (JNK)
inhibitor (B), phosphatidylinositol-4,5-bisphosphate 3-kinase(PI3K) inhibitor (C), and PDGFRa inhibitors (D, E) did
not block the effect of DW002, suggesting that DW002 does not act through these signaling pathways. *, DMSO
control=0.0012%. Bar graph values represent means of the triplicates and error bars represent standard deviation.
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Discussion
DW002 decreases cell proliferation likely through downregulation of PDGFRa
From the cell viability and cytotoxicity assays, we found that treatment with DW002 led
to decreased cell viability but not increased cell death. From these results, we concluded that the
compound must be inhibiting cell proliferation. The untreated cells were able to grow normally,
leading to an increased number of cells and increased cell viability. In contrast, the cells treated
with DW002 stopped proliferating, leading to fewer cells after two days of treatment and a
decreased cell viability compared to control. It is unlikely that DW002 decreased cell viability
through a cytotoxic effect because cell death was not increased with treatment with DW002. We
expected DW002 to inhibit proliferation because it was already observed that DW002 decreases
transcription of PDGFRa. As mentioned in the introduction, PDGFRa is important for OPC
proliferation and differentiation. Proliferation of OPCs is dependent on signaling by PDGF-AA
through PDGFRa (Calver et al., 1998). Therefore, it makes sense that decreased expression of
PDGFRa due to DW002 would lead to decreased proliferation.
We also investigated the specificity of DW002. PDGFRa and PDGFRb are structurally
very similar, so we wanted to determine that the activity of DW002 was specific to PDGFRa.
Therefore, we used qPCR to determine if DW002 also led to decreased transcription of
PDGFRb. However, we found that PDGFRb is not expressed on Oli-neu cells. This result is
somewhat helpful, because now we know that DW002 could only be affecting PDGFRa
transcription in our model. This supports our hypothesis that the PDGFRa downregulation
caused by DW002 is responsible for the decreased cell proliferation. However, we have not
determined if DW002 does affect PDGFRb transcription. This is important to know because the
two receptor subtypes have different function in disease as well as in normal physiology. We
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want any therapeutic compound to treat glioma to have targeted activity against PDGFRa to
decrease tumor growth. Downregulating PDGFRb may have negative consequences. Therefore,
in would be useful to conduct more studies in the future with perhaps a different model to
determine the effect of DW002 on PDGFRb transcription.

DW002 does not appear to affect p38MAPK, JNK, PI3K, or PDGFRa signaling
We conducted the assays with the inhibitors to determine if DW002 had an effect on
certain cell signaling pathways. The cell signaling pathways we decided to inhibit were chosen
based on evidence that it may lead to PDGFRa transcription or because they were known to lead
to OPC proliferation. OPC proliferation in response to PDGF-AA is primarily mediated by
activation of PI3K which leads to Akt activation (Hill et al., 2013). DW002 may inhibit a
component of this signaling pathway, which may be why it inhibits cell proliferation. However,
we did not find that PI3K inhibition affected the proliferation of these cells. Therefore, it is
unlikely that DW002 acts through that mechanism.
p38MAPK is involved in OPC differentiation into oligodendrocytes (Baron et al., 2000).
It has been shown that p38MAPK phosphorylation increases as PDGFRa expressing progenitor
cells differentiate (Chew et al., 2010). PDGFRa is downregulated when OPCs begin to
differentiate (Hart, 1989). Therefore, it may be possible that p38MAPK may be involved in OPC
differentiation by regulating the transcription of PDGFRa. In fact, there is evidence to support
this. Activation of p38MAPK has been associated with a decrease in PDGFRa mRNA (Vela et
al., 2002). In addition, p38MAPK activates a transcription factor C/EBPβ (CCAAT/enhancerbinding protein) which represses PDGFRa transcription (Afink et al, 2004). p38MAPK also
inhibits the activity of JNK, which normally activates ATF2 (activator of transcription factor 2)
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(Chew et al, 2010; Lau et al., 2012). ATF2 stimulates PDGFRa transcription (Maekawa et al.,
1999). We thought it may be possible that DW002 decrease PDGFRa transcription by activating
the p38MAPK-C/EBPβ pathway or activating the p38MAPK/JNK/ATF2 pathway to decrease
PDGFRa transcription, and therefore inhibit cell proliferation. However inhibition of p38MAPK
did not block the effect of DW002 on cell proliferation. Inhibition of JNK similarly did not affect
DW002 activity. Therefore, it is unlikely that the mechanism of DW002 activity involves
modulation of these pathways. A summary of the pathways inhibited is depicted in Figure 10.

Figure 10. Simplified diagram depicting the signaling pathways that DW002 may be affecting to cause
downregulation of PDGFRa. Stimulation of PDGFRa by PDGF ligands leads to activation of JNK, p38MAPK,
and PI3K. JNK and p38MAPK can alternatively be activated by environmental stressors. It has been
previously shown that activation of JNK leads to increased transcription of PDGFRa, while activation of
p38MAPK leads to decreased transcription of PDGFRa through different transcription factors (ATF2 and
EBPβ). p38MAPK decreases the activity of JNK. Oli-neu cells were treated with various inhibitors (red
boxes) against PDGFRa, JNK, p38MAPK, and PI3K with or without DW002.
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There are some possible limitations to these experiments with the inhibitors. One is that
the inhibitors may inhibit more than the target that we intended. We tried to choose inhibitors
that were selective for each kinase or receptor, but there are very few inhibitors that are entirely
selective. For example, Ponatinib is an inhibitor of PDGFRa with an IC50 of 1.1 nM, but it also
inhibits VEGFR2 (IC50-1.5 uM) and FGFR1 (IC50=2.2 uM). Another limitation is that the
concentrations chosen may not adequately inhibit the intended target. We used a wide range
around the IC50 of the inhibitors, but a higher concentration may be needed to adequately inhibit
the target in the cells.
A major limitation to this experiment, as well as the other experiments, is that our model,
an Oli-neu cell line, may not perfectly represent human OPCs. From the data, we saw that
PDGFRa inhibitors did not inhibit the proliferation of the cells. However, previous experiments
have found that OPCs are dependent on PDGF-AA signaling through PDGFRa to proliferate.
Oli-neu cell growth independent of PDGFRa signaling may be because it is a cell line
transformed with an ErbB2 oncogene (Jung et al., 1995). This oncogene may provide enough
signals for proliferation so that other growth factor signaling pathways are not necessary. The
fact that Oli-neu cells do not require PDGFRa signaling to proliferate indicates that PDGFRa
downregulation may not be the mechanism by which DW002 inhibits cell proliferation. To
investigate this further, we will test an inhibitor of ErbB2 to determine if blocking that pathway
inhibits growth of the cells. If so, DW002 may be affecting a component of that signaling
pathway, therefore causing the decreased cell proliferation.
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iTRAQ analysis did not yield any clear protein changes involved in DW002 mechanism of action
Along with the inhibitor treatments, we also used iTRAQ analysis to elucidate the
possible mechanism of action of DW002. We were able to identify proteins that were up or down
regulated after treatment with DW002 but not treatment with DW006. I used UniProt to find the
function of proteins found to be hits using Method 1 and strong hits using Method 2. The
descriptions of the proteins from UniProt are listed in Table 2. The proteins that are less
expressed after treatment with DW002 appear to be proteins involved in glycolysis, transcription,
and cell division. This is expected, because we already know that DW002 leads to decreased cell
proliferation. Cells treated with DW006 or untreated cells undergo more cell proliferation, so
they require the activity of proteins involved in growth and division. Of note, one of the proteins
identified through Method 2 that was downregulated was Notchless Protein Homolog 1.
Evidence has shown that this protein downregulates p21, which is a cyclin dependent kinase
inhibitor. This finding is interesting because Jelena previously found that DW002 decreases
transcription of p21 (Medved, 2014). Taken together, this supports the idea that DW002 blocks
cell cycle progression of the cells and leads to decreased proliferation.
Of the upregulated proteins after DW002 treatment, Histone H4 makes sense because
with less cell division, there is less DNA replication and transcription, so the DNA can stay more
tightly coiled around histones. It is unclear why 40S Ribosomal Protein S19 is upregulated. I
would expect it to be downregulated because there is less transcription and translation occurring
after DW002 treatment. Molybdopterin synthase catalytic subunit is also upregulated. This
cofactor is necessary for some metabolizing enzymes. It may be upregulated because the cells
are metabolizing the DW002 compound. The last protein that is upregulated is calmodulin. This
could be involved in a multitude of processes. It is difficult to determine why it is upregulated
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with DW002 treatment. It may be useful to further investigate the pathways that calmodulin is
involved in.
There were no clear signaling pathways that were up or down regulated due to DW002
treatment. Many of the proteins that had altered expression were just indicators of decreased cell
proliferation, and did not provide any mechanistic information. However, before drawing any
final conclusions, it is necessary to further analyze the data we received from iTRAQ. The
methods that I used to identify protein hits may not be the best way to find altered protein
expression. This was just preliminary work to get an idea of what may be occurring. While the
criteria to classify proteins as “abnormal” was objective, choosing the criteria of less than the
25th percentile and greater than the 75th percentile was a subjective decision. It would be useful to
use actual proteomics software to glean more information, and to identify a way to actually
determine if protein expression after DW002 is significantly different from the control or
treatment with DW006.
In the preparation for iTRAQ, the cells were treated with DW002 for a long and short
incubation. The short incubation was about 20 hours and the long incubation was about 30 hours.
Both of these incubations were shorter than how the cells were treated for all of the previous
experiments. Therefore, we may not have captured proteins that were altered at later time points.

Future directions and significance
Through the methods and experiments described so far, we have been able to confirm
that DW002 decreases Oli-neu cell proliferation. It has a much more robust and potent effect
than DW006, despite having almost identical structures. This indicates that the small difference
in the structure of DW002 is important for its activity. We have also investigated the mechanism
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by which DW002 has this effect, but so far have been unsuccessful in determining a clear target.
More research needs to be conducted to elucidate DW002’s mechanism of action. As previously
mentioned, Oli-neu cells are not a perfect representation of OPCs. Therefore, we will next try to
determine the pathways that regulate Oli-neu cell proliferation to identify possible pathways that
DW002 may be modulating. We will use lapatinib to inhibit ErbB2 and see if the effect of
DW002 is maintained. We will also use a different model, mouse slice culture, to retest the
previous inhibitors and see if the results match the Oli-neu cell results. It would also be helpful to
test DW002 on glioma models or samples to see if it has a true beneficial effect.
Further investigation into the mechanism of DW002 may help to identify new targets for
the development of glioma treatments. Once we can identify how DW002 is decreasing
proliferation, we can try to improve its activity through structure activity relationship studies. We
could also develop new compounds to target other components of the pathway that DW002
modulates. The goal is to develop therapeutic compounds that could decrease the proliferation of
glioma cells, thereby inhibiting tumor formation. Future studies into DW002 may also be
beneficial for other CNS diseases where PDGFRa plays a role. For example, downregulation of
PDGFRa may inhibit the proliferation of OPCs, allowing them to differentiate into
oligodendrocytes that remyelinate nerves, a possible therapy for multiple sclerosis. Therefore,
the research conducted thus far is the beginning of work that could help to find therapeutic
compounds for glioma and other diseases as well.
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